http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2452436-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6379feda6e2eb9af0653088fc5870448 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
| filingDate | 2011-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f637a16c8f7926b6f7299467f3a86785 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_664b52638a9e1c105cfb4a49cf798b7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_322519d37f40c3b43f7f019b35fc64f5 |
| publicationDate | 2012-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2452436-C1 |
| titleOfInvention | Method of treating optic nerve atrophy of vascular genesis |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to ophthalmology and is intended for treatment of optic nerve atrophy of vascular genesis. For this purpose pterygopalatine (PP) and submustoidal (SM) blockades are performed to patient with application of medicinal mixture, 7-9 blockades per course with time interval 22-24 hours. After that, discrete plasmapheresis in amount 3-5 procedures with time interval 48-72 hours is performed, with volume of exfusion for a procedure constituting 20-25% of circulating blood volume. Then extracorporal pharmacotherapy is carried out. Activation of cell mass, obtained in carrying out plasmapheresis, is performed with gliatilin in dose 500-1000 mg, with further reinfusion of activated cell mass intravenously, by drip infusion. To perform PP medicinal mixture, containing lidocaine 50-100 mg, gliatilin 250-500 mg, lidase 16-32 U, is used. To perform SM medicinal mixture, containing lidocaine 50-100 mg, cortexin 5-10 mg, lidase 16-32 U, is used. n EFFECT: invention ensures efficient treatment of disease with reduction of labour-consumption and simplification of method. n 2 cl, 3 ex |
| priorityDate | 2011-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.